Received Nov 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
The patient stated that they had a 3 into 4-inch patch of redness; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site erythema in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site erythema (Verbatim: The patient stated that they had a 3 into 4-inch patch of redness). The outcome of the injection site erythema was not reported. It was unknown if the reporter considered the injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site erythema to be related to Shingrix. Additional Information: GSK Receipt Date: 16-NOV-2025 The patient reported that they understood redness around the injection site was a common side effect of Shingrix. However, they questioned whether a large red area was also normal. The patient stated that they had a 3 into 4-inch patch of redness two days after receiving the injection. The batch number was not provided, and we are unable to contact the reporter.